Lifeboat Foundation

Russian biophysicist Alexei Karnaukhov wants to stop our natural aging process with the help of gene therapy, and he successfully completed the first part of his experiment to increase longevity.

NASA is offering $1.1 million in prize money in Phase 2 of the 3D-Printed Habitat Challenge for new ways to build houses where future space explorers can live and work.

The three-part competition asks citizen inventors to use readily available and recyclable materials for the raw material to print habitats.

Phase 2 focuses on the material technologies needed to manufacture structural components from a combination of indigenous materials and recyclables, or indigenous materials alone. NASA may use these technologies to construct shelters for future human explorers to Mars. On Earth, these same capabilities could also be used to produce affordable housing wherever it is needed or where access to conventional building materials and skills is limited.

Continue reading “NASA Offers Prize Money for 3D-Printed Habitat Ideas” »

The new method could play a key role in helping scientists take carbon dioxide out of the air to fight climate change.

CRISPR Therapeutics—a Swiss startup hoping to harness the gene-editing technology it’s named after to develop treatments for genetic illnesses like sickle-cell anemia and cystic fibrosis— went public today (Oct. 19), raising $56 million in its initial public offering. It’s the third CRISPR-related biotech to IPO this year despite a pitched battle over who owns the patent to the breakthrough technique.

The market for CRISPR (short for “clustered regularly interspaced short palindromic sequences”) is projected to be worth more than $5.5 billion by 2021, nearly double its current value, according to research firm MarketsandMarkets. The potential of the cheap, easy-to-use technology—which could do everything from creating a mushroom that doesn’t brown to curing cancer by cutting and pasting snippets of DNA—has companies rushing to develop new applications even though no one knows who will ultimately control it.

“It’s a race,” says Fabien Palazzoli, head of biotech intellectual property (IP) analytics for the consulting firm IPStudies. “It’s a race for the IPO, for the scientific results, for the FDA recommendation, for the IP.”

Continue reading “CRISPR-based startups rush to IPO and don’t seem to care that we don’t know who officially owns CRISPR” »

A group of scientists has managed to overcome the theoretical limit on image sharpness.

Read more

” … the ECB urged EU lawmakers to tighten proposed new rules on digital currencies such as bitcoin …”

Read more

PCG-1α therapy shows promise in treating age-related decline.

It is always a good idea to look closely at the biochemistry involved in any potential Alzheimer’s disease therapy that shows promise in mouse models. There is perhaps more uncertainty for Alzheimer’s than most other age-related conditions when it comes to the degree to which the models are a useful representation of the disease state in humans — which might go some way towards explaining the promising failures that litter the field. In the research here, the authors are aiming to suppress a step in the generation of amyloid-β, one of the proteins that aggregates in growing amounts and is associated with brain cell death in Alzheimer’s disease. They achieve this goal using gene therapy to increase the level of PGC-1α, which in turn reduces the level of an enzyme involved in the production of amyloid-β. Interestingly, increased levels of PGC-1α have in the past been shown to produce modest life extension in mice, along with some of the beneficial effects to health associated with calorie restriction.

Quote:

Continue reading “PGC-1α Gene Therapy Slows Alzheimer’s Progression in Mouse Model” »

Time to get the toothbrush out and brush for longevity!

For decades, research has suggested a link between oral health and inflammatory diseases affecting the entire body — in particular, heart attacks and strokes.

The results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD®), show statistically significant reductions in dental plaque and inflammation throughout the body. Inflammation throughout the body is accurately measured by high sensitivity C-reactive protein (hs-CRP), a sensitive marker for future heart attacks and strokes. These results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD®, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.

Continue reading “Toothpaste significantly reduces dental plaque and inflammation throughout the body” »